Company / Cash & Equivalents
Harmony Biosciences Holdings, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$752.5M
FY2025
5-year range
$234.3M / $752.5M
FY2021-FY2025
Trend
+66.1%
vs FY2024
Sector context
#25 of 207
Health Care
What the data says
Harmony Biosciences Holdings, Inc.'s cash & equivalents of $753M is higher than 88% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 6 consecutive years, from $24M in FY2019 to $753M in FY2025.
Based on SEC 10-K filings.
$753M in FY2025 with a 5-year CAGR of +26.9%. Top quartile in the Health Care sector.
Improved from $312M to $753M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +45.6%
- 5-Year CAGR
- +26.9%
- 10-Year CAGR
- -
Sector benchmark
+12.4% above sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s cash & equivalents has grown for 6 consecutive years.
- 5-year CAGR of +26.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 66.1% year-over-year.
- Ranks #25 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $752.5M | +66.1% |
| FY2024 | $453.0M | +45.4% |
| FY2023 | $311.7M | +27.8% |
| FY2022 | $243.8M | +4.0% |
| FY2021 | $234.3M | +2.5% |
| FY2020 | $228.6M | +834.8% |
| FY2019 | $24.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026